奥沙利铂联合表柔比星经肝动脉化疗栓塞治疗原发性肝癌的研究  

Study on Oxaliplatin Combined Epirubicin via Transcatheter Arterial Chemoembolization in Treatment of Primary Liver Cancer

作　　者：赵越[1] 吴耀华[1] ZHAO Yue;WU Yao-hua(First Affiliated Hospital of Harbin Medical University (Harbin Heilongjiang, 150001)China)

机构地区：[1]哈尔滨医科大学附属第一医院,黑龙江哈尔滨150001

出　　处：《中西医结合肝病杂志》2019年第2期130-132,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：国家自然科学基金资助项目(No.81502605)

摘　　要：目的:观察奥沙利铂联合表柔比星经肝动脉化疗栓塞(TACE)治疗原发性肝癌的效果及安全性。方法:80例原发性肝癌患者按随机数字表法分为对照组(单纯碘油TACE)和观察组(奥沙利铂联合表柔比星经TACE),对比两组患者治疗总有效率、1年生存率;比较两组患者术前、治疗3周、治疗6周血清甲胎蛋白(AFP)、癌胚抗原(CEA)水平;并对比两组患者不良反应发生率。结果:观察组患者总有效率(92.50%)较对照组(72.50%)高,1年生存率(75.00%)较对照组患者(60.00%)高;治疗3周时观察组患者CEA水平降低且低于对照组患者,治疗6周时观察组AFP、CEA均降低且低于对照组患者;观察组患者血小板减少率(10.00%)、白细胞减少率(22.50%)、中性粒细胞减少率(22.50%)均低于对照组。上述比较均有统计学差异,P均<0.05。结论:奥沙利铂联合表柔比星-TACE能提高原发性肝癌患者治疗效果,降低肿瘤标志物水平,减少不良反应,提高1年生存率,值得临床应用。Objective:To evaluate the efficacy and safety of oxaliplatin plus epirubicin in transcatheter arterial chemoembolization in pa-tients with primary liver cancer. Methods: This study was a prospective study. According to the criteria of this study,80 patients with primary liver cancer were included in the study. Patients were divided into control group(transcatheter arterial chemoembolization alone)and observa- tion Group(oxaliplatin combined with epirubicin transcatheter hepatic artery chemoembolization) by random number table,the total effective rate and 1-year survival rate were compared between the two groups;compared two groups of preoperative and postoperative treatment serum alpha-fetoprotein (AFP) and carcinoembryonic antigen(CEA) for 6 weeks. The incidence of adverse reactions was compared between the two groups. Results:The total effective rate(92. 50%) in the observation group was higher than that in the control group(72. 50%),and the 1- year survival rate was 75. 00%(60. 00%)higher than that in the control group Group,the AFP and CEA in the observation group decreased and were lower than those in the control group after 6 weeks of treatment. The incidences of thrombocytopenia(10. 00%), leukopenia (22. 50%)and neutropenia(22. 50% lower than the control group. The above comparison were statistically significant(P < 0. 05). Conclu- sion:Oxaliplatin combined with epirubicin via transcatheter arterial chemoembolization could improve the therapeutic effect of primary liver cancer,reduce the level of tumor markers,reduce adverse reactions and improve 1-year survival rate,which is worthy of application.

关 键 词：奥沙利铂 表柔比星 肝动脉化疗栓塞术 原发性肝癌 疗效 

分 类 号：R735.7[医药卫生—肿瘤]